Cytokinetics launches Myqorzo as 275 prescribers fuel early uptake

Cytokinetics Inc. has entered its first year as a commercial-stage biotech after the FDA approved Myqorzo for obstructive hypertrophic cardiomyopathy, with more than 275 healthcare providers prescribing the drug by the end of the first quarter.

"The early adoption metrics reflect strong physician engagement and a clear unmet need in oHCM," a company spokesperson said, noting that more than 70 percent of patients on therapy had transitioned to paid prescriptions.

Approximately 680 patients had been prescribed Myqorzo by the end of Q1, with the US commercial rollout beginning in January 2026. The European Commission followed with approval in February, and the first EU launch occurred in Germany. Cytokinetics is also pursuing a label expansion: the FDA accepted its supplemental new drug application for MAPLE-HCM, a Phase 3 study comparing aficamten as monotherapy against metoprolol, with a target action date of Nov. 14, 2026.

The approval transforms Cytokinetics from a development-stage company dependent on partnership revenue into a revenue-generating drugmaker, but it faces entrenched competition from Bristol Myers Squibb's Camzyos and generic beta blockers that remain first-line standard of care. The company's ability to capture market share will depend on how quickly it can differentiate Myqorzo's safety and efficacy profile in real-world practice.

Lifecycle Data Could Broaden the Addressable Market

Beyond the initial oHCM indication, Cytokinetics is building a broader case for aficamten. The Phase 3 ACACIA-HCM study in non-obstructive hypertrophic cardiomyopathy met both co-primary endpoints, showing statistically significant improvements from baseline through week 36 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and maximal exercise performance measured by peak VO2. Statistically significant improvements were also observed in key secondary endpoints.

If approved for nHCM, the addressable patient population would expand considerably. Non-obstructive HCM accounts for roughly one-third of all hypertrophic cardiomyopathy cases, according to published estimates. The MAPLE-HCM head-to-head trial against metoprolol, if positive, could further shift prescribing patterns away from generic beta blockers toward aficamten as first-line therapy.

Commercial Execution and the Competitive Landscape

Cytokinetics has deployed a tailored commercialization model featuring dedicated cardiac account specialists and patient support programs — a strategy designed to drive adoption among cardiologists who have long relied on beta blockers, calcium channel blockers, or Camzyos. Bristol Myers Squibb's Camzyos, also a cardiac myosin inhibitor, launched earlier and has had more time to establish prescribing habits.

The company's cash position and burn rate will be closely watched by investors as it scales commercial infrastructure. Biotech companies transitioning to commercial stage typically face a period of elevated spending before revenue reaches breakeven. Cytokinetics has not yet disclosed updated cash runway guidance following the launch.

International expansion provides an additional growth lever beyond the US and Germany. The European Commission approval covers all EU member states, and the drug is already approved in China, giving Cytokinetics access to two of the world's largest pharmaceutical markets.

This article is for informational purposes only and does not constitute investment advice.